Compare CRBP & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRBP | NCSM |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oilfield Services/Equipment |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 170.3M |
| IPO Year | 2014 | 2017 |
| Metric | CRBP | NCSM |
|---|---|---|
| Price | $11.46 | $41.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $45.50 | N/A |
| AVG Volume (30 Days) | ★ 290.4K | 40.6K |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 239.22 |
| EPS | N/A | ★ N/A |
| Revenue | $4,822,272.00 | ★ $142,471,000.00 |
| Revenue This Year | N/A | $5.57 |
| Revenue Next Year | $116.00 | $4.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $6.73 | $28.65 |
| 52 Week High | $20.56 | $87.36 |
| Indicator | CRBP | NCSM |
|---|---|---|
| Relative Strength Index (RSI) | 69.55 | 30.36 |
| Support Level | $9.32 | $35.23 |
| Resistance Level | $11.64 | $43.62 |
| Average True Range (ATR) | 0.70 | 5.29 |
| MACD | 0.08 | -3.26 |
| Stochastic Oscillator | 91.59 | 6.19 |
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completion, and field development strategies. The company provides its products and services to E&P companies for use in onshore and offshore wells, predominantly those drilled with horizontal laterals in unconventional and conventional oil and natural gas formations. It also provides tracer diagnostics services and sells products for well construction including casing buoyancy systems, liner hanger systems and toe initiation sleeves, along with certain complementary products from third parties. The company operates in the United States, Canada and other countries, with the majority of its revenue generated from Canada.